Mersana Therapeutics, Inc. (MRSN) Q3 2022 Earnings Call Transcript

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET

Company Participants

Jason Fredette - Senior Vice President, Investor Relations and Corporate Communications
Anna Protopapas - President and Chief Executive Officer
Arvin Yang - Senior Vice President and Chief Medical Officer
Brian DeSchuytner - Senior Vice President and Chief Financial Office

Conference Call Participants

Jonathan Chang - SVB Securities
Colleen Kusy - Baird
Kaveri Pohlman - BTIG
David Nierengarten - Wedbush
Boris Peaker - Cowen & Co

Operator

Good morning, and welcome to Mersana Therapeutics Third Quarter 2022 Conference Call and webcast. Currently, all participants are in a listen-only mode. There will be a question answer session at the end of this call.

I would now like to turn the call over to Jason Fredette, Senior Vice President, Investor Relations and Corporate Communications. Please proceed.

Jason Fredette

Good afternoon, everyone. Before we begin, please note that this call will contain forward-looking statements within the meaning of the federal securities laws. These statements may include, but are not limited to, those related to the therapeutic potential of our product candidates and the potential of our platform, business strategy, clinical trial, design initiation, execution and data releases, regulatory plans and objectives, commercial opportunities, collaborations and potential associated payments, operating expenses and cash runway. Each of these forward-looking statements is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements.

These risks and uncertainties are discussed in the company's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022 and in subsequent SEC filings. Our filings are available at sec.gov or on our website, mersana.com. Except as required by law, we assume no obligation to update forward-looking statements publicly even if new information becomes available in the future.